Results 111 to 120 of about 11,492 (193)
Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1
Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a progressive disease with only one approved treatment currently available.
Zemin Ji +16 more
core +1 more source
MAFLD/MASLD: Past, Present, and Future
Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2882-2892, September 2026.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease and metabolic dysfunction‐associated fatty liver disease, affects more than 30% of the global adult population and has become one of the leading causes of cirrhosis and hepatocellular carcinoma.
Vincent Wai‐Sun Wong
wiley +1 more source
Fatty liver disease - non alcoholic to metabolic - A transition of concepts!!
Journal of Family Medicine and Primary CareMetabolic dysfunction associated fatty liver disease (MAFLD) was a concept suggested lately. Initially, the only criterion for the diagnosis of MAFLD was the absence of alcohol intake. With rising prevalence and studies assessing this condition, certain “
Nipun Bawiskar +2 more
doaj +1 more source
Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice
Physiological Reports, Volume 14, Issue 17, September 2026.Loss of glyoxalase 1 has a minimal impact on protein glycation in a murine model for metabolic syndrome. These mice have reduced hepatic steatosis despite impaired glucose handling. Abstract We demonstrate the generation and characterization of the methylglyoxal detoxifying enzyme, glyoxalase 1, knockout mice (Glo1−/−).
Emely A. Hoffman +16 more
wiley +1 more source
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials [PDF]
Clinical and Molecular Hepatology, 2023 Ming-Lun Yeh, Ming-Lung Yu
doaj +1 more source
Adding to the confusion in more than just the name [PDF]
Clinical and Molecular Hepatology, 2023 Jacob George
doaj +1 more source
Clinical Interventions in Aging, 2020 Zhan Gu,1,* Yan Bi,2,* Fan Yuan,2,* Ruirui Wang,1 Dong Li,3 Jianying Wang,1 Xiaojuan Hu,1 Guang He,2 Lei Zhang,1 Bao-cheng Liu1 1Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203 ...
Gu Z +9 more
doaj
The contribution of genetics and epigenetics to MAFLD susceptibility [PDF]
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide. The risk of developing MAFLD varies among individuals, due to a combination of environmental inherited and acquired genetic factors.
Stefano Romeo +5 more
core +1 more source
Background: Metabolic dysfunction associated fatty liver disease (MAFLD) is a highly prevalent non-communicable disease whose prevalence is reaching pandemic proportions. Its implications constitute a major public health concern.
Samah Al Tawil +6 more
core +1 more source
A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells
Frontiers in Bioscience-LandmarkBackground: Disease risk variants are likely to affect gene expression in a context- and cell-type specific manner. The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs8736 metabolic-dysfunction-associated fatty liver disease (MAFLD)-risk
Ziyan Pan +4 more
doaj +1 more source